Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:BEAM NASDAQ:DNLI NYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$13.61-0.9%$15.82$4.06▼$24.27$715.48M0.831.08 million shs1.34 million shsBEAMBeam Therapeutics$32.84+11.1%$28.64$15.60▼$36.44$3.38B2.252.04 million shs4.39 million shsDNLIDenali Therapeutics$20.14+2.4%$19.69$12.58▼$23.77$3.20B1.031.74 million shs1.83 million shsRCUSArcus Biosciences$24.83+4.1%$23.71$7.91▼$28.72$3.12B0.851.20 million shs632,445 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics-1.58%-12.98%+0.22%-21.84%+212.27%BEAMBeam Therapeutics+2.04%-7.34%-3.79%+15.79%+75.06%DNLIDenali Therapeutics+1.60%-2.72%+7.43%-0.20%+41.13%RCUSArcus Biosciences-2.20%-0.80%-7.16%+8.07%+138.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$13.61-0.9%$15.82$4.06▼$24.27$715.48M0.831.08 million shs1.34 million shsBEAMBeam Therapeutics$32.84+11.1%$28.64$15.60▼$36.44$3.38B2.252.04 million shs4.39 million shsDNLIDenali Therapeutics$20.14+2.4%$19.69$12.58▼$23.77$3.20B1.031.74 million shs1.83 million shsRCUSArcus Biosciences$24.83+4.1%$23.71$7.91▼$28.72$3.12B0.851.20 million shs632,445 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics-1.58%-12.98%+0.22%-21.84%+212.27%BEAMBeam Therapeutics+2.04%-7.34%-3.79%+15.79%+75.06%DNLIDenali Therapeutics+1.60%-2.72%+7.43%-0.20%+41.13%RCUSArcus Biosciences-2.20%-0.80%-7.16%+8.07%+138.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 2.83Moderate Buy$48.13253.60% UpsideBEAMBeam Therapeutics 2.71Moderate Buy$46.8342.61% UpsideDNLIDenali Therapeutics 2.87Moderate Buy$34.2570.06% UpsideRCUSArcus Biosciences 2.58Moderate Buy$35.1041.36% UpsideCurrent Analyst Ratings BreakdownLatest AVTX, DNLI, RCUS, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026RCUSArcus Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$46.005/26/2026AVTXAvalo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $35.005/22/2026DNLIDenali Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$31.005/21/2026BEAMBeam Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.005/18/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00 ➝ $35.005/14/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $40.005/14/2026AVTXAvalo Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$62.00 ➝ $55.005/14/2026AVTXAvalo Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $34.005/14/2026AVTXAvalo Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$39.00 ➝ $45.005/14/2026AVTXAvalo Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $35.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$60K11,924.63N/AN/A$4.49 per share3.03BEAMBeam Therapeutics$139.74M24.18N/AN/A$12.20 per share2.69DNLIDenali Therapeutics$330.53M9.67N/AN/A$6.91 per share2.91RCUSArcus Biosciences$247M12.64N/AN/A$5.84 per share4.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$78.26M-$5.46N/AN/AN/AN/A-97.54%-72.42%8/6/2026 (Estimated)BEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)DNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)RCUSArcus Biosciences-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)Latest AVTX, DNLI, RCUS, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026AVTXAvalo Therapeutics-$1.00-$0.98+$0.02-$0.98$0.05 millionN/A5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million3/23/2026Q4 2025AVTXAvalo Therapeutics-$1.54-$0.37+$1.17-$0.37($0.21) million$0.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A7.667.66BEAMBeam Therapeutics0.0916.9916.99DNLIDenali Therapeutics0.019.289.28RCUSArcus Biosciences0.194.044.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%BEAMBeam Therapeutics99.68%DNLIDenali Therapeutics92.92%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics4.46%BEAMBeam Therapeutics3.80%DNLIDenali Therapeutics12.50%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4052.57 million50.22 millionNot OptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableRCUSArcus Biosciences500125.77 million113.70 millionOptionableAVTX, DNLI, RCUS, and BEAM HeadlinesRecent News About These CompaniesArcus, Bristol Myers Team Up to Advance Kidney Cancer StudyJune 4 at 12:55 PM | zacks.comLifesci Capital Initiates Coverage on Arcus Biosciences (NYSE:RCUS)June 4 at 12:52 PM | marketbeat.comArcus to Supply Experimental Kidney Cancer Drug for Myers Squibb TrialJune 3 at 9:42 AM | marketwatch.comArcus Biosciences (NYSE:RCUS) CAO Sells $66,022.74 in StockJune 2 at 5:17 AM | insidertrades.comFisher Asset Management LLC Increases Position in Arcus Biosciences, Inc. $RCUSMay 27, 2026 | marketbeat.comArcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceMay 26, 2026 | businesswire.comArcus Biosciences, Inc. $RCUS Shares Sold by Sectoral Asset Management Inc.May 25, 2026 | marketbeat.comNewsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue ForecastsMay 17, 2026 | finance.yahoo.comArcus Biosciences (NYSE:RCUS) CFO Sells $198,965.69 in StockMay 13, 2026 | insidertrades.comVanguard Group Inc. Has $189.76 Million Position in Arcus Biosciences, Inc. $RCUSMay 11, 2026 | marketbeat.comAnalyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter ReportMay 9, 2026 | finance.yahoo.comArcus Biosciences (NYSE:RCUS) Cut to Sell at Wall Street ZenMay 9, 2026 | marketbeat.comHC Wainwright Expects Higher Earnings for Arcus BiosciencesMay 8, 2026 | marketbeat.comThe Goldman Sachs Group Forecasts Strong Price Appreciation for Arcus Biosciences (NYSE:RCUS) StockMay 7, 2026 | marketbeat.comArcus outlines PEAK-1 full enrollment by year-end 2026 with cash runway into 2H 2028May 6, 2026 | seekingalpha.comArcus Biosciences, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 6, 2026 | seekingalpha.comArcus Biosciences, Inc. (NYSE:RCUS) Q1 2026 Earnings Call TranscriptMay 6, 2026 | insidermonkey.comArcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comArcus Biosciences (NYSE:RCUS) Issues Earnings ResultsMay 5, 2026 | marketbeat.comArcus (RCUS) Q1 2026 Earnings Call TranscriptMay 5, 2026 | finance.yahoo.comArcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue EstimatesMay 5, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVTX, DNLI, RCUS, and BEAM Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$13.61 -0.13 (-0.95%) Closing price 04:00 PM EasternExtended Trading$13.88 +0.27 (+1.95%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Beam Therapeutics NASDAQ:BEAM$32.84 +3.29 (+11.13%) Closing price 04:00 PM EasternExtended Trading$32.71 -0.13 (-0.38%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Denali Therapeutics NASDAQ:DNLI$20.14 +0.48 (+2.44%) Closing price 04:00 PM EasternExtended Trading$19.88 -0.27 (-1.32%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Arcus Biosciences NYSE:RCUS$24.83 +0.97 (+4.07%) Closing price 03:59 PM EasternExtended Trading$24.83 0.00 (0.00%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
